

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



TYK Medicines, Inc

浙江同源康醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2410)

**APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR;
CHANGE IN COMPOSITION OF THE BOARD COMMITTEES ;
AND COMPLIANCE WITH RULE 3.10(2), 3.21, 3.25 AND 3.27A OF
THE LISTING RULES**

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Director(s)**”) of TYK Medicines, Inc (浙江同源康醫藥股份有限公司) (the “**Company**”) is pleased to announce that Mr. JIANG Xiaolin (“**Mr. Jiang**”) has been appointed as an independent non-executive Director, chairman of the audit committee (the “**Audit Committee**”) of the Board, and a member of each of the remuneration and appraisal committee (the “**Remuneration Committee**”) and the nomination committee (the “**Nomination Committee**”) of the Board with effect from December 12, 2025. The biographical details of Mr. Jiang are set out as below:

Mr. Jiang, aged 60, has over 35 years of experience in the field of accounting, auditing and financial management. Since October 2025, he has served as the deputy chief accountant of Huzhou Jinling Yongda Accounting Firm (General Partnership) (湖州金陵永達會計師事務所(普通合夥)). Mr. Jiang began his career working for the Changxing County Audit Bureau of Zhejiang Province. From January 2000 to May 2011, he worked at Changxing Yongcheng United Certified Public Accountants (General Partnership) (長興永誠聯合會計師事務所(普通合夥)), where he last served as their chief accountant. Subsequently, from June 2011 to December 2013, he worked at Zhejiang Puhua Certified Public Accountants Co., Ltd. (浙江普華會計師事務所有限公司), where he last served as a department manager. From January 2014 to December 2019, he worked at Zhejiang Henghui Certified Public Accountants Co., Ltd. (浙江恒惠會計師事務所有限公司), where he last served as a department manager. From January 2020 to March 2025, Mr. Jiang worked at Zhejiang Zhengrui Certified Public Accountants (General Partnership) (浙江正瑞會計師事務所(普通合夥)), where he last served as their chief accountant.

Mr. Jiang obtained a bachelor degree in mathematical statistics from Hangzhou University (currently known as Zhejiang University) in July 1989. He is also qualified as a certified public accountant in the People's Republic of China in May 1996.

The Company has entered a service contract with him, the term of which shall commence from the date of his appointment and end on the expiration of the term of office of the second session of the Board (subject to retirement and re-election as and when required under the articles of association of the Company). Mr. Jiang is entitled to a director's fee of RMB144,000 per annum (before tax) as specified in the terms of his appointment, which was determined by the Board (the decision of which was based on the recommendation of the Remuneration Committee) with reference to his duties and responsibilities within the Group and the prevailing market rate for similar position. Such remuneration is subject to review by the Remuneration Committee from time to time.

As at the date of this announcement and save as disclosed above, Mr. Jiang confirms that (i) he meets the independence criteria pursuant to Rule 3.13 of the Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited (the "**Listing Rules**"); (ii) that he has no past or present financial or other interest in the business of the Company or its subsidiaries or any connection with any core connected person (as defined in the Listing Rules) of the Company; and (iii) that there are no other factors that may affect his independence at the time of his appointment. He did not have any relationship with any director, senior management, chief executive, substantial shareholder or controlling shareholder of the Company and hold no other position within the Company and other members of the Group. Within the meaning of Part XV of the Securities and Futures Ordinance, Mr. Jiang also confirms that he does not have and deemed to have any interest in the shares or underlying shares of the Company or associated corporations and he has not held any directorship in any other listed public companies whose shares were listed in Hong Kong or any overseas stock exchange in the last three years and he does not have any major appointments and professional qualifications. There is no other matter that needs to be brought to the attention of the shareholders of the Company or the Stock Exchange of Hong Kong Limited and there is no other information which is required to be disclosed pursuant to any of the requirements of Rule 13.51(2) of the Listing Rules.

CHANGE IN COMPOSITION OF THE BOARD COMMITTEES

Immediately upon the appointment of Mr. Jiang with effect from December 12, 2025, Mr. Jiang has been appointed as chairman of the Audit Committee and a member of each of the Remuneration Committee and the Nomination Committee.

The Company also announce that with effect from December 12, 2025, Dr. GU Eric Hong, a non-executive Director, has been appointed as a member of the Audit Committee and that Dr. LI Jun, a non-executive Director, has ceased to be a member of the Audit Committee. Dr. LI Jun has ceased to be a member of the Audit Committee in order to devote more time to his other business and personal commitments.

Following the changes, the Audit Committee consists of three members, names, Mr. Jiang (chairman), Dr. GU Eric Hong and Dr. LENG Yuting. Dr. LI Jun has confirmed that he has no disagreement with the Audit Committee and is not aware of other matters about his cessation as a member of the Audit Committee that need to be brought to the attention of the shareholders of the Company and The Stock Exchange of Hong Kong Limited.

The Board would like to take this opportunity to express its sincere gratitude to Dr. LI Jun for his contribution as a member of the Audit Committee and welcome Mr. Jiang and Dr. GU Eric Hong to their new appointments.

COMPLIANCE WITH RULES 3.10(2), 3.21, 3.25 AND 3.27A OF THE LISTING RULES

Reference is made to the announcement of the Company dated September 15, 2025 in relation to the resignation of Mr. ZHANG Senquan and the temporary non-compliance with Rules 3.10(2), 3.21, 3.25 and 3.27A of the Listing Rules.

Following the appointment of Mr. Jiang as an independent non-executive Director, chairman of the Audit Committee and a member of each of the Remuneration Committee and the Nomination Committee with effect from December 12, 2025, the Company has resumed compliance with Rules 3.10(2), 3.21, 3.25 and 3.27A of the Listing Rules.

By order of the Board
TYK Medicines, Inc
(浙江同源康醫藥股份有限公司)
Dr. WU Yusheng

Chairman, Executive Director and Chief Executive Officer

Hong Kong, December 12, 2025

As at the date of this announcement, the Board comprises Dr. WU Yusheng as executive Director, Dr. LI Jun, Dr. GU Eric Hong, Dr. JIANG Mingyu, Mr. HE Chao and Dr. ZHU Xiangyang as non-executive Directors, and Dr. LENG Yuting, Dr. XU Wenqing, Dr. SHEN Xiuhua and Mr. JIANG Xiaolin as independent non-executive Directors.